Ultragenyx (RARE) competitors & alternatives
Health Care · NASDAQ
Ultragenyx (RARE)'s top competitors and alternatives — its most similar public companies — include BioMarin Pharmaceutical (BMRN), REGENXBIO INC (RGNX), AGIOS PHARMACEUTICALS INC (AGIO), AMYLYX PHARMACEUTICALS INC (AMLX), XERIS BIOPHARMA HOLDINGS INC (XERS), MIRUM PHARMACEUTICALS INC (MIRM), Alnylam Pharmaceuticals (ALNY), NOVARTIS AG (NVS), ROCKET PHARMACEUTICALS INC (RCKT), TRAVERE THERAPEUTICS INC (TVTX), SPRUCE BIOSCIENCES INC (SPRB) and SAVARA INC (SVRA). These are Ultragenyx's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top RARE competitors & alternatives
-
BioMarin PharmaceuticalBMRNHealth Care
BioMarin is a global rare disease biotech company delivering genetic medicines across enzyme therapies, growth disorders, metabolic diseases, and gene…
$58.40 (as of 2026-07-22) · market cap $11.3B
-
REGENXBIO INCRGNXHealth Care
Clinical-stage gene therapy company using proprietary NAV vectors to deliver functional genes for rare genetic and retinal disorders through partnerships with…
$10.20 (as of 2026-07-22) · market cap $529M
-
AGIOS PHARMACEUTICALS INCAGIOHealth Care
A commercial-stage biopharmaceutical company focused on transforming the treatment landscape for rare genetic hematologic diseases through its innovative…
$36.05 (as of 2026-07-22) · market cap $2.2B
-
AMYLYX PHARMACEUTICALS INCAMLXHealth Care
Clinical-stage biotech developing novel therapies for endocrine and neurodegenerative disorders, with a lead GLP-1 receptor antagonist for post-bariatric…
$17.70 (as of 2026-07-22) · market cap $2.0B
-
XERIS BIOPHARMA HOLDINGS INCXERSHealth Care
A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug…
$8.38 (as of 2026-07-22) · market cap $1.5B
-
MIRUM PHARMACEUTICALS INCMIRMHealth Care
Mirum is a rare disease biopharmaceutical company commercializing approved bile acid and hepatic therapies while advancing late-stage candidates in cholestatic…
$114.48 (as of 2026-07-22) · market cap $7.0B
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
NOVARTIS AGNVS
Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
$153.08 (as of 2026-07-22) · market cap $229.2B
-
ROCKET PHARMACEUTICALS INCRCKTHealth Care
Rocket Pharmaceuticals is a clinical-stage biotechnology company developing transformative gene therapies for rare, high-unmet-need genetic disorders.
$3.30 (as of 2026-07-22) · market cap $368M
-
TRAVERE THERAPEUTICS INCTVTXHealth Care
Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first…
$56.26 (as of 2026-07-22) · market cap $5.2B
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
Not quite? Describe exactly what you want →
Peers are Ultragenyx's closest public companies by shared sub-industry, sector and business themes. See the full profile: Ultragenyx (RARE).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.